Asenapine

Nat Rev Drug Discov. 2009 Nov;8(11):843-4. doi: 10.1038/nrd3027.

Abstract

In August 2009, asenapine (Saphris; Schering-Plough) was approved by the US FDA for the acute treatment of schizophrenia and manic or mixed episodes associated with bipolar I disorder in adults.

MeSH terms

  • Adult
  • Antipsychotic Agents / adverse effects
  • Antipsychotic Agents / pharmacology
  • Antipsychotic Agents / therapeutic use*
  • Bipolar Disorder / drug therapy*
  • Bipolar Disorder / physiopathology
  • Dibenzocycloheptenes
  • Drug Approval
  • Heterocyclic Compounds, 4 or More Rings / adverse effects
  • Heterocyclic Compounds, 4 or More Rings / pharmacology
  • Heterocyclic Compounds, 4 or More Rings / therapeutic use*
  • Humans
  • Randomized Controlled Trials as Topic
  • Schizophrenia / drug therapy*
  • Schizophrenia / physiopathology
  • United States
  • United States Food and Drug Administration

Substances

  • Antipsychotic Agents
  • Dibenzocycloheptenes
  • Heterocyclic Compounds, 4 or More Rings
  • asenapine